• γH2AX DNA Damage Detection Kit: Precision in DNA DSB Detecti

  2026-07-13

  The γH2AX DNA Damage Detection Kit (Mouse mAb/Red) empowers researchers to visualize and quantify DNA double-strand breaks with high sensitivity. Its robust immunofluorescence workflow accelerates genotoxicity and DNA repair studies, offering reliable results for radiotherapy, apoptosis, and advanced translational research.

• Hypoxia and Immunometabolism: Mechanisms Shaping Tumor Micro

  2026-07-13

  This review synthesizes current understanding of how hypoxia-driven metabolic reprogramming and immunometabolic interactions shape the tumor microenvironment and facilitate tumor progression. It highlights both the mechanistic basis and therapeutic implications of targeting these processes in oncology research.

• Tioconazole in Antifungal Research: Mechanistic Insights and

  2026-07-12

  Explore how Tioconazole, a leading antifungal medication, advances research through precise ergosterol biosynthesis inhibition and high-purity applications. Gain unique mechanistic perspectives and actionable assay protocols in this in-depth cornerstone article.

• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-07-10

  Schwartz's dissertation advances in vitro drug testing by dissecting the interplay between proliferative arrest and cell death in cancer cells, challenging the reliance on single-metric readouts. This approach enables more nuanced evaluation of tyrosine kinase inhibitors and anti-angiogenic agents, with practical implications for drug screening and mechanistic oncology research.

• Foretinib (GSK1363089): Applied Protocols for Tumor Cell Inh

  2026-07-09

  Foretinib (GSK1363089) empowers researchers to dissect tumor cell proliferation and metastasis with nanomolar-precision across diverse cancer models. This practical guide details robust workflows, troubleshooting, and evidence-driven optimization strategies to maximize reproducibility and data impact using APExBIO’s multikinase inhibitor.

• Amyloid Beta-peptide (25-35): Bridging Model Precision and M

  2026-07-09

  Explore how Amyloid Beta-peptide (25-35) (Aβ25-35) advances Alzheimer's disease neurotoxicity models by enabling nuanced microglial studies and translational assay decisions. This article uniquely unpacks the peptide’s mechanistic depth and practical workflow insights for neurodegenerative disease research.

• Leupeptin Hemisulfate Salt: Expanding Protease Inhibition Fr

  2026-07-08

  Explore the advanced mechanistic insights and emerging applications of Leupeptin hemisulfate salt in protease activity regulation, protein degradation studies, and viral replication inhibition. This in-depth review introduces new scientific perspectives and protocol strategies for biochemical research.

• Low-Dose Orlistat Enhances Oxaliplatin Response in Colorecta

  2026-07-08

  This study demonstrates that low-dose orlistat synergistically increases the efficacy of oxaliplatin in colorectal cancer, both in vitro and in patient-derived xenograft models. The findings highlight a promising strategy to overcome chemoresistance and improve therapeutic outcomes by targeting apoptosis pathways.

• Remimazolam Ameliorates POCD via Hippocampal HIF-1α Modulati

  2026-07-07

  This study demonstrates that remimazolam improves postoperative cognitive dysfunction (POCD) by downregulating hippocampal HIF-1α expression and reducing neural cell apoptosis. The use of YC-1, a selective HIF-1α inhibitor, reveals that targeting this pathway is central to mitigating POCD, offering mechanistic insight and translational potential for neuroprotection strategies.

• SARS-CoV-2 Nucleocapsid Disrupts GADD34-Driven Immune Signal

  2026-07-07

  This study reveals how the SARS-CoV-2 nucleocapsid protein impairs host innate immunity by sequestering GADD34 mRNA into atypical stress granule-like foci, thereby inhibiting IRF3-mediated interferon responses. These insights advance our mechanistic understanding of viral immune evasion and may inform research into therapeutic modulation of stress granule dynamics.

• CP-673451: Selective PDGFRα/β Inhibitor for Tumor Models

  2026-07-06

  CP-673451 stands out in preclinical cancer research as a highly selective PDGFRα/β inhibitor, delivering robust angiogenesis inhibition and tumor suppression, especially in genetically defined models like ATRX-deficient glioma. This article translates cutting-edge reference findings into actionable protocols, troubleshooting tips, and strategic insights for oncology laboratories seeking next-level precision.

• Nintedanib (BIBF 1120): Antiangiogenic Mechanisms and Protoc

  2026-07-06

  Nintedanib (BIBF 1120) is a nanomolar-potency triple angiokinase inhibitor with robust evidence for antiangiogenic and antifibrotic effects. Its selective inhibition of VEGFR, FGFR, and PDGFR supports applications in cancer and idiopathic pulmonary fibrosis models. This dossier integrates peer-reviewed data and validated workflows for translational research.

• Dovitinib (TKI-258): Advancing Translational Oncology Resear

  2026-07-05

  Explore how Dovitinib (TKI-258, CHIR-258), a multitargeted receptor tyrosine kinase inhibitor, is reshaping translational cancer research through precision pathway inhibition, robust apoptosis induction, and strategic workflow integration. This thought-leadership piece bridges mechanistic insights with actionable guidance for research teams tackling RTK-driven malignancies and highlights new directions for experimental design.

• HNF4A-AS1 Loss Drives Sorafenib Resistance via Lipid Metabol

  2026-07-04

  This study demonstrates that decreased expression of the liver-specific lncRNA HNF4A-AS1 promotes resistance to sorafenib-induced ferroptosis in hepatocellular carcinoma (HCC) by reprogramming cellular lipid metabolism. These findings highlight a mechanistic pathway involving m6A-mediated regulation of DECR1, providing new insight into overcoming drug resistance in liver cancer.

• Pazopanib (GW-786034): Targeting ATRX-Deficient Tumors in Ca

  2026-07-03

  Explore how Pazopanib (GW-786034) advances cancer research by selectively inhibiting key receptor tyrosine kinases and offering unique advantages for studying ATRX-deficient tumor models. Discover protocol insights, mechanistic depth, and actionable strategies distinct from standard angiogenesis workflows.

7498 records 13/500 page Previous Next First page 上5页 1112131415 下5页 Last page